Indivior allegedly misled healthcare providers and insurers into thinking that Suboxone Film was safer and harder to abuse than other opioid-addiction treatments. The company also sought to boost profits by using a “Here to Help” telephone and internet program that linked opioid-dependent patients to physicians who prescribed opioids at high rates, prosecutors charged.
By engaging in these behaviors, the drugmaker obtained billions of dollars in fraudulent revenue, the U.S. charges.
Indivior has denied the charges.
More articles on pharmacy:
PBM hearing should prompt bill to ban ‘secrecy’ in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy
